These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 22691895)

  • 41. [Standard pharmacological treatment and new therapies for overactive bladder].
    Del Popolo G; Mencarini M; Li Marzi V
    Urologia; 2012; 79(1):6-13. PubMed ID: 22344568
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The second-line management of idiopathic overactive bladder: what is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice?
    Chapple C; De Ridder D
    BJU Int; 2009 Nov; 104(9):1188-90. PubMed ID: 19681899
    [No Abstract]   [Full Text] [Related]  

  • 43. [Idiopathic overactive bladder: What to do in case of anticholinergic failure?].
    Boudy AS; Thubert T
    Prog Urol; 2015 Jun; 25(8):497-8. PubMed ID: 25748787
    [No Abstract]   [Full Text] [Related]  

  • 44. Medical treatment of female overactive bladder syndrome and treatment-related effects.
    Hsiao SM; Lin HH
    J Formos Med Assoc; 2018 Oct; 117(10):871-878. PubMed ID: 29398096
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Muscarinic receptor antagonists for overactive bladder.
    Abrams P; Andersson KE
    BJU Int; 2007 Nov; 100(5):987-1006. PubMed ID: 17922784
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Management of refractory idiopathic overactive bladder: intradetrusor injection of botulinum toxin type A versus posterior tibial nerve stimulation.
    Sherif H; Khalil M; Omar R
    Can J Urol; 2017 Jun; 24(3):8838-8846. PubMed ID: 28646940
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Shifting the treatment paradigm in idiopathic overactive bladder.
    Sahai A; Belal M; Hamid R; Toozs-Hobson P; Granitsiotis P; Robinson D
    Int J Clin Pract; 2021 Apr; 75(4):e13847. PubMed ID: 33220129
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia.
    Chapple CR; Siddiqui E
    Expert Rev Clin Pharmacol; 2017 Feb; 10(2):131-151. PubMed ID: 28001447
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mirabegron: A new option in treating overactive bladder.
    Turpen HC; Zimmern PE
    JAAPA; 2015 Nov; 28(11):16, 18. PubMed ID: 26501573
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Early investigational β3 adreno-receptor agonists for the management of the overactive bladder syndrome.
    Thiagamoorthy G; Giarenis I; Cardozo L
    Expert Opin Investig Drugs; 2015; 24(10):1299-306. PubMed ID: 26292923
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Second-line therapy of idiopathic detrusor overactivity. Sacral neuromodulation and botulinum toxin A].
    Amend B; Castro-Diaz D; Chartier-Kastler E; De Ridder D; Everaert K; Spinelli M; van Kereebroeck P; Sievert KD
    Urologe A; 2010 Feb; 49(2):245-52. PubMed ID: 19859688
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety and tolerability of β3-adrenoceptor agonists in the treatment of overactive bladder syndrome - insight from transcriptosome and experimental studies.
    Michel MC; Gravas S
    Expert Opin Drug Saf; 2016 May; 15(5):647-57. PubMed ID: 26954275
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Overactive bladder--a practical approach to evaluation and management.
    Madersbacher H
    J Med Liban; 2004; 52(4):220-6. PubMed ID: 16432986
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combination Pharmacotherapy for Treatment of Overactive Bladder (OAB).
    El-Zawahry A
    Curr Urol Rep; 2019 May; 20(6):33. PubMed ID: 31098731
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Posterior tibial nerve stimulation vs parasacral transcutaneous neuromodulation for overactive bladder in children.
    Barroso U; Viterbo W; Bittencourt J; Farias T; Lordêlo P
    J Urol; 2013 Aug; 190(2):673-7. PubMed ID: 23422257
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Overactive bladder: diagnosis and management.
    Robinson D; Cardozo L
    Maturitas; 2012 Feb; 71(2):188-93. PubMed ID: 22197347
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The role of antimuscarinics in the management of men with symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an update.
    Athanasopoulos A; Chapple C; Fowler C; Gratzke C; Kaplan S; Stief C; Tubaro A
    Eur Urol; 2011 Jul; 60(1):94-105. PubMed ID: 21497434
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The pharmacokinetic evaluation of mirabegron as an overactive bladder therapy option.
    Kashyap M; Tyagi P
    Expert Opin Drug Metab Toxicol; 2013 May; 9(5):617-27. PubMed ID: 23550899
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial.
    Peters KM; Macdiarmid SA; Wooldridge LS; Leong FC; Shobeiri SA; Rovner ES; Siegel SW; Tate SB; Jarnagin BK; Rosenblatt PL; Feagins BA
    J Urol; 2009 Sep; 182(3):1055-61. PubMed ID: 19616802
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Profile of mirabegron in the treatment of overactive bladder: place in therapy.
    Sharaf A; Hashim H
    Drug Des Devel Ther; 2017; 11():463-467. PubMed ID: 28255232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.